Selection of house dust mite-allergic patients by molecular diagnosis may enhance success of specific immunotherapy
To the Editor:
House dust mites (HDMs) are one of the most potent and frequent allergen sources worldwide. 1 More than 40% of patients with allergy are sensitized to HDM allergens and suffer from allergic symptoms such as rhinoconjunctivitis, atopic dermatitis, and allergic asthma, the most severe form of respiratory allergy. 2 The HDM Dermatophagoides pteronyssinus contains several different allergens of which Der p 1, Der p 2, Der p 5, Der p 7, Der p 21, and Der p 23 are the clinically most relevant allergens according to the frequency of IgE sensitization and the ability to induce allergic reactions. 3 Allergen-specific immunotherapy (AIT) is effective and safe for the treatment of HDM allergy, 4 but it has been shown that HDM extracts vary regarding the contents of important HDM allergens and extracts used for AIT are standardized only for Der p 1 and Der p 2 according to the guidelines of the European Medicines Agency. 5, 6 Here, we performed a post hoc analysis of sera from HDM-allergic patients who had been treated by subcutaneous HDM AIT in a double-blind, placebo-controlled clinical study (see Fig E1 in this article's Online Repository at www.jacionline.org), regarding their IgE and IgG reactivity against a comprehensive panel of HDM allergens by ImmunoCAP ISAC technology. The clinical effects of AIT had been evaluated in the patients by controlled allergen exposure in the Vienna Challenge Chamber.
We found that subjects who were treated with verum and placebo showed comparable IgE reactivity profiles at baseline. Der p 1, Der p 2, and Der p 23 were the most frequently recognized D pteronyssinus allergens (78%, 94%, and 79%, respectively); Der p 5 (61%), Der p 4 (52%), Der p 7 (44%), and Der p 21 (45%) were also frequently recognized, whereas the other tested allergens were recognized by less than 40% of the patients (see Fig E2, A, and Tables E1 and E2 in this article's Online Repository at www.jacionline.org). The levels of allergen-specific IgE antibodies were highest for Der p 2 (mean, 36.52 ISAC standardized units [ISUs] ), followed by Der p 1 (mean, 9.35 ISUs) and Der p 23 (mean, 8.23 ISUs) (see Tables  E1-E3 in this article's Online Repository at www.jacionline. org). Der p 1, 2, 5, 7, 21, and 23 are important allergens because they have been shown to induce strong immediate-type reactions by provocation testing and/or basophil degranulation, whereas IgE levels to Der p 4 were low in the patients tested ( Fig E2, A  and B ) and Der p 4 shows low allergenic activity in basophil degranulation assays (Y. Resch and S. Vrtala, unpublished data, 2019). Fifty-seven of the study patients (verum, 28; placebo, 29) were challenged with HDMs in a challenge chamber (see this article's Online Repository at www.jacionline.org). These patients showed similar IgE-binding frequencies and IgE levels to the HDM allergens as did the total study population and the verum and placebo groups were comparable (Fig E2, B ; Table E3 ). (Fig 1, A) , whereas IgG levels to the other important HDM allergens (ie, Der p 23, Der p 5, Der p 7, and Der p 21) (Fig 1) showed no relevant changes as compared with those at baseline. Likewise, IgG against the less relevant HDM allergens except Der p 4 remained unchanged in the verum group during treatment ( Fig E3) . In the placebo groups, the IgG levels to all tested HDM allergens remained constant during AIT (Fig 1 and  Fig E3) . There are several possible explanations for the selective induction of IgG antibodies to Der p 2 and Der p 1 by the HDM vaccine. In fact, it has been shown that HDM allergen extracts mainly contain Der p 2 and Der p 1, whereas other HDM allergens are poorly represented in the allergen extracts. 5 It is also possible that mainly Der p 2 and Der p 1 were immunogenic, whereas the other allergen molecules in the allergen extract exhibited poor immunogenicity and hence did not induce IgG responses as has been shown for grass pollen allergen extracts. 7 The strong induction of Der p 2-specific IgG antibodies in the active group was associated with a significant decrease in IgE binding to Der p 2 in the chip measurements. We assume that this decrease in IgE binding is due to the blocking of IgE binding to immobilized Der p 2 by the treatment-induced IgG antibodies, which we found also for patients who had received birch pollen and grass pollen allergen-specific AIT. 8 Because the induction of allergen-specific IgG-blocking antibodies is a major mechanism behind the clinical efficacy of AIT, we investigated whether the patients' molecular IgE reactivity profiles before treatment and the development of allergen-specific IgG antibodies in the course of treatment are associated with clinical effects of AIT. For 28 of the 52 verum and for 29 of the 48 placebo patients, respiratory symptoms (ie, total nasal symptoms tracked by using the total nasal symptom score [TNSS]) from controlled HDM exposure in the Vienna Challenge 
Chamber
9 were available for baseline and from weeks 23 and 47 (see this article's Online Repository at www.jacionline.org). The TNSS at baseline was comparable for the verum and placebo subjects (see Fig E4, Total, in this article's Online Repository at www.jacionline.org) (Fig 2, Total) . At weeks 23 and 47, there was no relevant difference in the TNSS between verum and placebo subjects (Fig E4, Total) , although a trend toward reduction in the TNSS area under the curve was noted between week 0 and weeks 23 and 47 (Fig 2, Total) . When the patients were stratified according to their IgE reactivity profiles, we found that only actively treated patients who were exclusively sensitized to Der p 1 and/or Der p 2 showed lower TNSS compared with placebo after 23 and 47 weeks of treatment ( Fig E4, group 1) , reaching a statistically significant difference when the area under the curve was considered at week 47 (Fig 2, group 1) . In contrast, no signs of improvement were observed regarding TNSS in the patients who were additionally sensitized to 1 or more of the other important HDM allergens ( Fig E4; Fig 2, group 2) . Skin prick test (SPT) results were available from all 100 subjects at baseline and for weeks 23 and 47, but the limitations of the SPT data as compared with the challenge chamber data were (1) that SPT does not test for respiratory sensitivity, (2) allergen extracts used for skin testing mainly contain Der p 1 and Der p 2 5 but not the other allergens, whereas allergen extracts used in the challenge chamber contained the important HDM allergens, 9 and (3) no end-point titrations were performed. Regarding SPT the following observations were made: There was no significant difference between verum and placebo subjects at baseline (see Fig E5, A, in this article's Online Repository at www.jacionline. org). At weeks 23 and 47, skin sensitivity was significantly lower in the verum group compared with that in the placebo group for patients with exclusive IgE reactivity to Der p 1 and/or Der p 2 and for patients who were additionally sensitized to 1 or more of the other important HDM allergens (Fig E5, A, group 1, group 2). Similar results were obtained when the 57 patients (verum, 28; placebo, 29) who were challenged with HDMs in the challenge chamber were analyzed (Fig E5, B) . Both in the verum and placebo groups skin sensitivity was lower at week 23 and increased again at week 47.
Taken together our results demonstrate that AIT performed with HDM extracts inducing IgG antibodies mainly to Der p 1 and Der p 2 was beneficial for those patients who were sensitized exclusively to Der p 1 and/or Der p 2 but not for patients with sensitization to other HDM allergens. This study was performed with an HDM allergoid, but similar results were obtained with other HDM extracts (Rodriguez and Vrtala, unpublished data), probably because HDM extracts used for AIT are generally standardized only for Der p 1 and Der p 2. Limitations of our study are that (1) it was performed as a post hoc analysis, (2) our results are indirect and will be difficult to implement because there are currently no allergy vaccines with a complete HDM allergen profile available that would allow proving that such a vaccine will be superior, and (3) the numbers of patients that could be analyzed were limited. However, the study was performed in a blinded manner, and the detailed analysis of IgE and IgG responses to a representative panel of HDM allergen molecules together with the availability of precise challenge chamber data gave clear results. Our study suggests that molecular diagnosis may support allergists to identify patients who deserve AIT for HDM allergy with extracts currently available by companies, to increase the clinical efficacy of treatment. Biomay, Vienna, Austria, and Viravaxx, Vienna, Austria, and serves as a consultant for these companies. The rest of the authors declare that they have no relevant conflicts of interest.
Role of P2X3 receptors in scratching behavior in mouse models
To the Editor: Itch is an unpleasant cutaneous sensation that elicits a desire to scratch or scratch reflex. Itch generally serves as a warning and a self-protection mechanism against harmful external agents. However, chronic itch caused by multiple dermatological or systemic diseases (eg, atopic dermatitis) has strongly deleterious effects on the quality of life of millions of people worldwide. 1 Sensory information from the peripheral endings of primary afferent sensory neurons in the skin is conveyed through these neurons to the spinal dorsal horn (SDH), where it activates brainprojecting neurons via neural circuits. Neuronal pathways from the periphery to the brain selective for itch are still poorly understood, but recent studies have identified neuronal populations for itch at the levels of primary afferents and the SDH. 2 Han et al 3 showed that deleting a subpopulation of primary afferent sensory neurons that express Mas-related G proteincoupled receptor A3 (MrgprA3) led to a selective deficit in behaviors related to itch but not to pain, indicating that MrgprA3 1 primary sensory neurons are essential for itch sensation. However, little is known about endogenously expressed molecules that control the activity of this population. Because MrgprA3 1 neurons are also necessary for chronic itch, 3 the identification of such molecules controlling MrgprA3 1 neurons will help our understanding of the mechanism for acute and chronic itch and also provide a new therapeutic strategy for chronic itch.
In this study, we focused on P2X3 purinoceptors (P2X3Rs), a subtype of ATP-gated cation channels, because immunoreactivity for P2X3Rs has previously been detected in small-diameter dorsal root ganglion (DRG) and trigeminal (TG) neurons, including the MrgprA3 1 population. 3 However, it remains unknown whether P2X3Rs are functional in the MrgprA3 1 population and, more importantly, whether they play a role in itch sensation. Consistent with previous observations in lumbar DRG neurons, 3 we observed P2X3R immunofluorescence in cervical DRG neurons positive for green fluorescent protein (GFP) in Mrgpra3 GFP-Cre mice (Fig 1, A) in which GFP is expressed in the MrgprA3 1 neuronal population.
3 P2X3Rs were also observed in MrgprA3 1 fibers (tdTomato 1 ) in the skin of Mrgpra3 GFP-Cre ;ROSA26 tdTomato mice (Fig 1, B) , but P2X3R mRNA was extremely low in the skin (see Fig E1 in this article's Online Repository at www. jacionline.org). Thus, P2X3Rs are expressed in MrgprA3 1 nerve endings in the skin. We also found that 61.5% and 55.2% of chloroquine (an MrgprA3 agonist)-responded DRG and TG neurons, respectively, showed intracellular Ca 21 transients after application of a,b-methylene ATP (a,b-meATP), which activates P2X3Rs (Fig 1, C) To assess the ability of P2X3R agonists to produce itch, we monitored scratching behavior after intradermal injection of ATP or a,b-meATP to the rostral back in mice. Scratching directed to the injection site was elicited by either ATP or a,b-meATP (Fig 2,  A) . Similarly, in the cheek model, 4 an alternative behavioral assay for itch, these agonists when administered to the cheeks of mice increased scratching with the hindlimb (Fig 2, B; see Fig E3 in this article's Online Repository at www.jacionline.org). The a,b-meATP-induced scratching was prevented by A317491, a P2X3R-selective antagonist (Fig 2, B; see Fig E4 in this article's Online Repository at www.jacionline.org). By contrast, ATP and a,b-meATP did not induce wiping, a behavior that reflects painrelated responses in the cheek model (Fig 2, C) . These results indicate that activation of P2X3Rs in the skin elicits scratching. To determine whether MrgprA3 1 neurons mediate P2X3R-dependent scratching, we intradermally coadministered the lidocaine derivative QX-314 with chloroquine, a treatment that selectively silences MrgprA3 1 sensory neurons. 5 This treatment markedly suppressed scratching evoked by ATP and a,b-meATP (Fig 2, D) . Chloroquine or QX-314 alone had no effect on the a,bmeATP-induced scratching (data not shown). These results
METHODS

HDM-allergic patients and AIT
We performed a retrospective analysis of anonymized residual serum samples from HDM-allergic patients (n 5 100) who had participated in a randomized, double-blind, placebo-controlled, single-center AIT study (protocol PM/0008, dated September 17, 2001). The study was conducted in full compliance with the principals of the Declaration of Helsinki and in accordance with good clinical practice guidelines 2001/20/EG. The trial had been approved by the Clinical Pharmacology Ethics Committee, Vienna, Austria, and by the Austrian Regulatory Agency (AGES). Each subject participating in the trial signed an informed consent before entering the study, including a nonrestrictive consensus for anonymous investigations of their blood samples donated. The anonymized residual serum samples were analyzed for allergen-specific antibodies with permission from the Ethics Committee of the Medical University of Vienna (EK 1641/2014). The investigator analyzing the serum samples for allergen-specific IgE and IgG reactivities was blinded regarding whether the sera were from placebo-or verum-treated subjects and clinical parameters at the time of analysis.
Subjects in this study had undergone an initial screening visit with the first blood collection and a baseline HDM allergen challenge in an exposure chamber and were randomized 1:1 in a verum group and a placebo group. Sera from 52 subjects of the verum group and 48 subjects of the placebo group were available at baseline and from weeks 23 and 47 when additional challenge sessions were performed (Fig E1) . Verum subjects had been treated with subcutaneous injections of PURETHAL mite extract (Haarlems Allergen Laboratories, Haarlem, The Netherlands) starting with a build-up phase, where they had received weekly injections of increasing doses starting at 0.05 mL (1.000 AUeq) until week 5 when the maintenance dose of 0.5 mL (10.000 AUeq) had been reached. Then, subjects had received injections every 2 weeks until week 11 and from that point the treatment had been continued in monthly intervals until the end of the study at week 47. Fig E1 provides an overview of the study design showing the time points when blood samples were obtained, the time points and numbers of administered injections, and the administered doses. In the study, male and female subjects aged 18 to 65 years with rhinoconjunctivits and/or mild asthma related to HDMs for at least 2 years had been included. Inclusion criteria were (1) a positive skin prick test result (>histamine control) and a positive radioallergosorbent test result (> _ class 2) to D pteronyssinus at the screening visit, (2) a prechallenge FEV 1 of more than 70% of the predicted value, (3) symptomatic response to HDM challenge test defined as TNSS of 3 or more (out of a total of 9) at the screening visit to set up the baseline, and (4) HDM exposure at the homes of the study subjects. Exclusion criteria were sensitization to other allergens with clinically relevant symptoms, asthma (FEV 1 < 70%) or severe atopic dermatitis, and immunotherapy treatment with HDM within the last 5 years.
Nasal and skin sensitivity data of the subjects TNSS data were available for 57 subjects (verum: n 5 28; placebo: n 5 29). The TNSS data were derived from controlled HDM exposure that had been performed at week 0, 23, and 46 in the Vienna Challenge Chamber at the Allergy Center Vienna West as described. E1 HDM exposure had been performed for 165 minutes under constant humidity (;40%) and temperature (;248C), and subjects had scored every 15 minutes their symptoms for sneezing, rhinorrhea, and nasal pruritus on computer pads. Subjects had scored for each category with a score between 0 and 3: 0, absence of symptoms; 1, mild symptoms (symptoms clearly present, minimal awareness, easily tolerated); 2, moderate symptoms (definite awareness of the symptoms, bothersome but tolerable); 3, severe symptoms (symptoms hard to tolerate). The TNSS was calculated as sum of the 3 individual symptom scores and varied between 0 and 9 as recommended by the position paper of the European Academy of Allergy and Clinical Immunology. E2 HDM-specific skin sensitivity in the subjects had been determined by titrated SPTs performed in duplicates on the same days when the blood samples had been collected before the challenge chamber sessions (ie, weeks 0, 23, and 47). SPTs had been performed on the left forearm from proximal to distal in the following order: First positive control (0.1% histamine solution), second positive control (1% histamine solution), HDM extract in rising concentrations (10, 100, 1,000, 10,000 AU/mL), negative control (glycerol phosphate buffer solution) (Haarlems Allergen Laboratories), and on the right forearm in the reverse order starting with the negative control. The mean wheal diameters (Dm) were calculated from the maximal longitudinal (D) and the maximal transversal diameter (d) according to the formula [D 1 d]/2 5 Dm. The results of the SPT for the HDM extract are displayed as the means of sum of the Dm values from the left and right forearms for the 10,000 AU/mL concentrations. The concentration of 10,000 AU/mL was chosen because it was located in the increasing slope of sensitivity for all subjects.
Determination of allergen-specific IgE and IgG by microarray technology
IgE and IgG reactivity of sera from all subjects (n 5 100) and the 3 time 
Post hoc stratification of the patients according to IgE reactivity profiles
According to IgE reactivity profiles to the HDM allergens, 2 different patient groups were defined in a post hoc analysis. Group 1: Subjects with specific IgE only to Der p 1 and/or Der p 2. Group 2: Subjects sensitized to Der p 1 and/or Der p 2 and to 1 or more of the other relevant allergens (Der p 5, Der p 7, Der p 21, and Der p 23).
The numbers of subjects with available SPT data in the 2 groups were as follows: group 1: verum n 5 7; placebo: n 5 7; group 2 included 83 patients (45 in the verum group, 38 in the placebo group). Three patients from the placebo group sensitized exclusively to Der p 23 were not included in the stratification.
The numbers of subjects with available TNSS data in the 2 groups were as follows: clinical data from the Vienna Challenge Chamber were available for 57 patients, 28 from the verum group and 29 from the placebo group. Group 1 comprised 7 patients (4 in the verum group, 3 in the placebo group), and group 2 comprised 50 patients (24 in the verum group, 26 in the placebo group).
Display of results and statistical analysis
The descriptions of specific IgE levels and IgG levels, TNSS, and SPT results were displayed as box plot diagrams where 50% of the values are within the boxes and nonoutliers between the bars. Horizontal lines within the boxes indicate the median values. Open circles and stars indicate outliers and extreme values. For statistical analysis of the TNSS, the area under the curve was calculated for every patient and every time point of challenge according to the linear-trapezoidal rule.
E4
Unpaired Mann-Whitney tests were used to assess statistically significant differences between the verum and placebo groups and between different time points, and SPSS statistical software system (SPSS, Inc, Chicago, Ill) was used for calculations. The reported P values are the results of a 2-sided test, corrected by Shaffer coefficient. A P value of less than .05 has been considered as statistically significant. 
